China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality drug developer operating out of the United States and China. The agreement grants Duality Biologics global rights to Dartsbio’s in-house developed, potential first-in-class bispecific antibody (BsAb) DS005 to develop a new antibody drug conjugate (ADC). Dartsbio will receive an undisclosed amount in upfront payment, milestone payments, and sales commissions. Duality Biologics will enhance preclinical and clinical studies of the ADC.
DS005 Profile
Preclinical data has shown that DS005, with an undisclosed target, exhibits good anti-tumor activity and a favorable safety profile. This innovative bispecific antibody holds significant potential for the development of novel cancer therapies.
Duality Biologics Overview
Founded in January 2020, Duality Biologics focuses on oncology and autoimmune diseases. The company boasts a robust product pipeline consisting of nearly 10 best-in-class and first-in-class bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), with multiple candidates at clinical stages. This strategic partnership with Dartsbio underscores Duality Biologics’ commitment to advancing innovative therapies in oncology and autoimmune diseases.
Future Development
The licensing deal highlights the potential of DS005 to contribute to the development of next-generation cancer treatments. By leveraging Duality Biologics’ expertise in preclinical and clinical development, the partnership aims to accelerate the ADC’s progress through regulatory channels and bring a new therapeutic option to patients in need.-Fineline Info & Tech
